| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2716 |
| Trial ID | NCT04930770 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase2 |
| Recruitment status | Withdrawn |
| Title | Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination |
| Year | 2021 |
| Country | Spain |
| Company sponsor | Maria Joyera Rodríguez |
| Other ID(s) | 2021-002356-37 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||